ITG and NTP Cooperation - Milestone in Global Security of Supply for Radioisotope Industry

Informations

• Publié par: itg-isotope-technologies-garching-gmbh
• Nombre de lectures: 12
• Langue: English

Extrait

ITG and NTP Cooperation - Milestone in Global

Security of Supply for Radioisotope Industry

PR Newswire

GARCHING NEAR MUNICH, Germany, June 8, 2012

GARCHING NEAR

MUNICH, Germany

,

June 8, 2012

/PRNewswire/ --

ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative

radioisotopes - expands its nuclear reactor and technology network in line with

its strategy to guarantee global security of supply.

In

May 2012

, ITG - a fully-owned subsidiary of ITM Isotopen Technologien

München AG (ITM) based in

Germany

- and NTP Radioisotopes SOC Ltd (NTP) -

a subsidiary of the South African Nuclear Energy Corporation (NECSA) - agreed

on a substantial collaboration regarding radioisotopes. The cooperation is an

important milestone in ensuring a reliable supply of high quality radioisotopes

for

Africa

and

Brazil

. As a first step, NTP and ITG have agreed on a technology

transfer for the unique isotope ITG Lu-177 n.c.a. (non carrier added). In

addition, ITG will expand its already well-established global reactor network by

cooperating with NECSA's Safari-1 nuclear reactor.

Lutetium-177 plays a key role in nuclear medicine in the treatment of

neuroendocrine tumors, and has displayed strong growth potential. In

comparison to other production routes, every atom of the ITG Lu-177 n.c.a. is

radioactive. This results in specific activity many times higher than similar

products, therefore rendering treatments more effective. The contamination

with the long lived isomer Lu-177m is negligible. NTP has in-licensed the

production technology and will hence be the exclusive distribution partner for

ITG products in

Africa

.

Safari-1 nuclear reactor is one of only five reactors in the world, which together

produce 98% of the world's radionuclides for the medical sector. Steffen

Schuster, CEO of ITM states: "In the recent past, SAFARI-1 has been

instrumental in securing the supply of radiopharmaceuticals (via NTP) into the

world market when reactors were down due to unforeseen problems. It sends a

strong signal to those companies working with Lu-177-based therapies - global

supply is guaranteed and the agreement serves as proof of the value of our

production expertise.".

ITG is a well-established company in the supply of next generation isotopes and

technology. The company provides highly effective radioisotopes, such as the

ITG Lu-177 n.c.a., the ITG Ge-68/Ga-68 Generator and the ITG W-188/Re-188

Generator, as well as corresponding customized devices. ITG is renowned for its

dedicated team providing outstanding reliability in both quality and supply. ITG

has an esteemed global network of sales partners and strategic cooperations.

NTP is recognized as a leading global supplier of radioisotopes. NTP

manufactures a range of radioisotope products for use in downstream medical

devices and procedures as well as in industry. They have maintained consistent

growth in over 60 countries and in customers served.

The alliance of ITG and NTP will further enhance their international

competitiveness as well as reinforce their prominent position as a reliable and

attractive partner for their customers worldwide.

For further information and investor enquiries please contact:

ITG Isotope Technologies Garching GmbH, Dr. Richard Henkelmann, Managing

Director, [phone], [e-mail]